Leukemia, Myelodysplasia, Transplantation
Conference Coverage
CCC19, other registries help define COVID/cancer landscape
New data from CCC19 show an increased risk of death from COVID-19 among non-Hispanic black cancer patients and patients with hematologic...
Feature
In remission for 10 years: Long-term toxicity data on CAR T cells
Latest News
Don’t overlook treating older patients with acute promyelocytic leukemia, expert says
“Management options have changed dramatically with the advent of non–chemotherapy-based regimens.”
News
FDA approves oral therapy for myelodysplastic syndromes, CMML
Under a priority review, the FDA approved a combination tablet for treatment of people with myelodysplastic syndromes or chronic myelomonocytic...
Conference Coverage
Combo drug improves survival in older patients with high-risk/secondary AML
Conference Coverage
Venetoclax plus LDAC tops LDAC alone in AML
Conference Coverage
Azacitidine plus enasidenib improves response, but not survival, in mIDH2 AML
Enasidenib with, or after, azacitidine remains a question.
Conference Coverage
HSCT may be best option for therapy-related ALL
Conference Coverage
Ibrutinib-venetoclax produces high MRD-negative rates in CLL/SLL
Minimal residual disease was undetectable in peripheral blood of 75% of patients after an ibrutinib lead-in and 12 cycles of the combination.
Conference Coverage
First-in-kind anti-CD47 antibody shows promise for MDS and AML treatment
Conference Coverage
Omitting whole body irradiation before HSCT: Trial stopped early
“Our study shows significantly better outcomes for total body irradiation compared to myeloablative chemo-conditioning arms.”